Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2- breast cancer (LEADER).
Spring LM, Scarpetti L, Medford AJ, Niemierko A, Comander A, Mulvey T, Schnipper L, Isakoff SJ, Moy B, Wander SA, Shin J, Ephrem Z, Laposta AR, Denault E, Abraham E, Calistro G, Kalashnikova E, Rodriguez A, Liu MC, Aleshin A, Peppercorn J, Ellisen LW, Bardia A.
Spring LM, et al. Among authors: liu mc.
NPJ Breast Cancer. 2025 Jan 7;11(1):2. doi: 10.1038/s41523-024-00708-5.
NPJ Breast Cancer. 2025.
PMID: 39774684